Effects of combination M40403 and dexamethasone therapy on joint disease in a rat model of collagen-induced arthritis

Salvatore Cuzzocrea, Emanuela Mazzon, Rosanna Di Paola, Tiziana Genovese, Carmelo Muià, Achille P. Caputi, Daniela Salvemini, Alan Dunton

Research output: Contribution to journalArticle

Abstract

Objective. To investigate the effects of combination therapy with M40403, a superoxide dismutase mimetic (SODm), and dexamethasone (DEX) on collagen-induced arthritis (CIA) in rats. Methods. CIA was elicited in Lewis rats by an intradermal injection of 100 μl of an emulsion of bovine type II collagen (CII) in Freund's incomplete adjuvant (IFA) at the base of the tail. On day 21, a second injection of CII in IFA was administered at the base of the tail. Results. Lewis rats developed erosive arthritis of the hind paw when immunized with an emulsion of CII in IFA. The histopathology of CIA included erosion of the articular cartilage at the joint margins and subchondral bone resorption. Immunohistochemical analysis for nitrotyrosine, poly(ADP-ribose) polymerase (PARP), inducible nitric oxide synthase (iNOS), and cyclooxygenase 2 (COX-2) revealed positive staining in inflamed joints of collagen-treated rats. The combination therapy with M40403 2 mg/kg and DEX 0.01 mg/kg significantly reduced the development of the inflammatory process and reduced the degree of staining for iNOS, COX-2, nitrotyrosine, and PARP. No significant difference in the degree of staining between the combination therapy and the higher dose of DEX (0.1 mg/kg) was found. Furthermore, radiographic evidence of protection from bone resorption was apparent in the tibio-tarsal joints of rats that received the combination therapy. Conclusion. This study shows that combination therapy with M40403 and DEX reduced the degree of chronic inflammation and tissue and bone damage associated with CIA in the rat. It supports the possible use of SODm in combination with steroids to reduce the dose necessary and the side effects related to the use of steroids in the management of chronic diseases such as rheumatoid arthritis.

Original languageEnglish
Pages (from-to)1929-1940
Number of pages12
JournalArthritis and Rheumatism
Volume52
Issue number6
DOIs
Publication statusPublished - Jun 2005

Fingerprint

Experimental Arthritis
Joint Diseases
Dexamethasone
Poly(ADP-ribose) Polymerases
Nitric Oxide Synthase Type II
Cyclooxygenase 2
Bone Resorption
Staining and Labeling
Emulsions
Superoxide Dismutase
Tail
Therapeutics
Tarsal Joints
Joints
Steroids
Osteitis
Intradermal Injections
Collagen Type II
Articular Cartilage
Arthritis

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Effects of combination M40403 and dexamethasone therapy on joint disease in a rat model of collagen-induced arthritis. / Cuzzocrea, Salvatore; Mazzon, Emanuela; Di Paola, Rosanna; Genovese, Tiziana; Muià, Carmelo; Caputi, Achille P.; Salvemini, Daniela; Dunton, Alan.

In: Arthritis and Rheumatism, Vol. 52, No. 6, 06.2005, p. 1929-1940.

Research output: Contribution to journalArticle

Cuzzocrea, S, Mazzon, E, Di Paola, R, Genovese, T, Muià, C, Caputi, AP, Salvemini, D & Dunton, A 2005, 'Effects of combination M40403 and dexamethasone therapy on joint disease in a rat model of collagen-induced arthritis', Arthritis and Rheumatism, vol. 52, no. 6, pp. 1929-1940. https://doi.org/10.1002/art.21044
Cuzzocrea, Salvatore ; Mazzon, Emanuela ; Di Paola, Rosanna ; Genovese, Tiziana ; Muià, Carmelo ; Caputi, Achille P. ; Salvemini, Daniela ; Dunton, Alan. / Effects of combination M40403 and dexamethasone therapy on joint disease in a rat model of collagen-induced arthritis. In: Arthritis and Rheumatism. 2005 ; Vol. 52, No. 6. pp. 1929-1940.
@article{d0cc90effb0b4107bd98d79630aa7c28,
title = "Effects of combination M40403 and dexamethasone therapy on joint disease in a rat model of collagen-induced arthritis",
abstract = "Objective. To investigate the effects of combination therapy with M40403, a superoxide dismutase mimetic (SODm), and dexamethasone (DEX) on collagen-induced arthritis (CIA) in rats. Methods. CIA was elicited in Lewis rats by an intradermal injection of 100 μl of an emulsion of bovine type II collagen (CII) in Freund's incomplete adjuvant (IFA) at the base of the tail. On day 21, a second injection of CII in IFA was administered at the base of the tail. Results. Lewis rats developed erosive arthritis of the hind paw when immunized with an emulsion of CII in IFA. The histopathology of CIA included erosion of the articular cartilage at the joint margins and subchondral bone resorption. Immunohistochemical analysis for nitrotyrosine, poly(ADP-ribose) polymerase (PARP), inducible nitric oxide synthase (iNOS), and cyclooxygenase 2 (COX-2) revealed positive staining in inflamed joints of collagen-treated rats. The combination therapy with M40403 2 mg/kg and DEX 0.01 mg/kg significantly reduced the development of the inflammatory process and reduced the degree of staining for iNOS, COX-2, nitrotyrosine, and PARP. No significant difference in the degree of staining between the combination therapy and the higher dose of DEX (0.1 mg/kg) was found. Furthermore, radiographic evidence of protection from bone resorption was apparent in the tibio-tarsal joints of rats that received the combination therapy. Conclusion. This study shows that combination therapy with M40403 and DEX reduced the degree of chronic inflammation and tissue and bone damage associated with CIA in the rat. It supports the possible use of SODm in combination with steroids to reduce the dose necessary and the side effects related to the use of steroids in the management of chronic diseases such as rheumatoid arthritis.",
author = "Salvatore Cuzzocrea and Emanuela Mazzon and {Di Paola}, Rosanna and Tiziana Genovese and Carmelo Mui{\`a} and Caputi, {Achille P.} and Daniela Salvemini and Alan Dunton",
year = "2005",
month = "6",
doi = "10.1002/art.21044",
language = "English",
volume = "52",
pages = "1929--1940",
journal = "Arthritis care and research : the official journal of the Arthritis Health Professions Association",
issn = "0893-7524",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Effects of combination M40403 and dexamethasone therapy on joint disease in a rat model of collagen-induced arthritis

AU - Cuzzocrea, Salvatore

AU - Mazzon, Emanuela

AU - Di Paola, Rosanna

AU - Genovese, Tiziana

AU - Muià, Carmelo

AU - Caputi, Achille P.

AU - Salvemini, Daniela

AU - Dunton, Alan

PY - 2005/6

Y1 - 2005/6

N2 - Objective. To investigate the effects of combination therapy with M40403, a superoxide dismutase mimetic (SODm), and dexamethasone (DEX) on collagen-induced arthritis (CIA) in rats. Methods. CIA was elicited in Lewis rats by an intradermal injection of 100 μl of an emulsion of bovine type II collagen (CII) in Freund's incomplete adjuvant (IFA) at the base of the tail. On day 21, a second injection of CII in IFA was administered at the base of the tail. Results. Lewis rats developed erosive arthritis of the hind paw when immunized with an emulsion of CII in IFA. The histopathology of CIA included erosion of the articular cartilage at the joint margins and subchondral bone resorption. Immunohistochemical analysis for nitrotyrosine, poly(ADP-ribose) polymerase (PARP), inducible nitric oxide synthase (iNOS), and cyclooxygenase 2 (COX-2) revealed positive staining in inflamed joints of collagen-treated rats. The combination therapy with M40403 2 mg/kg and DEX 0.01 mg/kg significantly reduced the development of the inflammatory process and reduced the degree of staining for iNOS, COX-2, nitrotyrosine, and PARP. No significant difference in the degree of staining between the combination therapy and the higher dose of DEX (0.1 mg/kg) was found. Furthermore, radiographic evidence of protection from bone resorption was apparent in the tibio-tarsal joints of rats that received the combination therapy. Conclusion. This study shows that combination therapy with M40403 and DEX reduced the degree of chronic inflammation and tissue and bone damage associated with CIA in the rat. It supports the possible use of SODm in combination with steroids to reduce the dose necessary and the side effects related to the use of steroids in the management of chronic diseases such as rheumatoid arthritis.

AB - Objective. To investigate the effects of combination therapy with M40403, a superoxide dismutase mimetic (SODm), and dexamethasone (DEX) on collagen-induced arthritis (CIA) in rats. Methods. CIA was elicited in Lewis rats by an intradermal injection of 100 μl of an emulsion of bovine type II collagen (CII) in Freund's incomplete adjuvant (IFA) at the base of the tail. On day 21, a second injection of CII in IFA was administered at the base of the tail. Results. Lewis rats developed erosive arthritis of the hind paw when immunized with an emulsion of CII in IFA. The histopathology of CIA included erosion of the articular cartilage at the joint margins and subchondral bone resorption. Immunohistochemical analysis for nitrotyrosine, poly(ADP-ribose) polymerase (PARP), inducible nitric oxide synthase (iNOS), and cyclooxygenase 2 (COX-2) revealed positive staining in inflamed joints of collagen-treated rats. The combination therapy with M40403 2 mg/kg and DEX 0.01 mg/kg significantly reduced the development of the inflammatory process and reduced the degree of staining for iNOS, COX-2, nitrotyrosine, and PARP. No significant difference in the degree of staining between the combination therapy and the higher dose of DEX (0.1 mg/kg) was found. Furthermore, radiographic evidence of protection from bone resorption was apparent in the tibio-tarsal joints of rats that received the combination therapy. Conclusion. This study shows that combination therapy with M40403 and DEX reduced the degree of chronic inflammation and tissue and bone damage associated with CIA in the rat. It supports the possible use of SODm in combination with steroids to reduce the dose necessary and the side effects related to the use of steroids in the management of chronic diseases such as rheumatoid arthritis.

UR - http://www.scopus.com/inward/record.url?scp=20744445024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20744445024&partnerID=8YFLogxK

U2 - 10.1002/art.21044

DO - 10.1002/art.21044

M3 - Article

C2 - 15934059

AN - SCOPUS:20744445024

VL - 52

SP - 1929

EP - 1940

JO - Arthritis care and research : the official journal of the Arthritis Health Professions Association

JF - Arthritis care and research : the official journal of the Arthritis Health Professions Association

SN - 0893-7524

IS - 6

ER -